Lung Transplantation: Advances in Immunosuppression

Thoracic Surgery Clinics

Volumn 16, Issue 4, 2006, Pages 421-433

  Bush, Errol L ^a   Lin, Shu S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; MEPREDNISONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; THYMOCYTE ANTIBODY; TSUKUBAENOLIDE;

ACUTE GRAFT REJECTION; ADRENAL CORTEX INSUFFICIENCY; ANASTOMOSIS DEHISCENCE; BONE MARROW SUPPRESSION; BRADYCARDIA; BRAIN DISEASE; BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT REJECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CUSHING SYNDROME; CYTOKINE RELEASE; DIABETES MELLITUS; DIGESTIVE SYSTEM ULCER; DRUG INDUCED HEADACHE; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEMATOLOGIC DISEASE; HEMODIALYSIS; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPH NODE IRRADIATION; MYOPATHY; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; OSTEOPOROSIS; PANCYTOPENIA; PRIORITY JOURNAL; PUVA; REVIEW; SEIZURE; SERUM SICKNESS; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR DISEASE; VIRAL GENE THERAPY; WOUND HEALING IMPAIRMENT;

ANTIMETABOLITES, ANTINEOPLASTIC; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; LYMPHATIC IRRADIATION; PHOTOPHERESIS;

EID: 37849189132     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2006.07.002     Document Type: Review

References (74)

1. Holt D.W., Johnston A., Roberts N.B., et al. Methodological and clinical aspects of cyclosporin monitoring: report of the Association of Clinical Biochemists task force. Ann Clin Biochem 31 (1994) 420-446
2. Jaksch P., Kocher A., Neuhauser P., et al. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). J Heart Lung Transplant 24 8 (2005) 1076-1080
3. Studer S.M., Levy R.D., McNeil K., et al. Lung transplant outcomes: a review of survival, graft function, physiology, health-related quality of life and cost-effectiveness. Eur Respir J 24 4 (2004) 674-685
4. Herve P., Silbert D., Cerrina J., et al. Impairment of bronchial mucociliary clearance in long-term survivors of heart/lung and double-lung transplantation. The Paris-Sud Lung Transplant Group. Chest 103 1 (1993) 59-63
5. Higenbottam T., Jackson M., Woolman P., et al. The cough response to ultrasonically nebulized distilled water in heart-lung transplantation patients. Am Rev Respir Dis 140 1 (1989) 58-61
6. Palmer S.M., Burch L.H., Trindade A.J., et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 171 7 (2005) 780-785
7. Cantu III E., Appel III J.Z., Hartwig M.G., et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. [discussion]. Ann Thorac Surg 78 4 (2004) 1142-1151
8. Davis Jr. R.D., Lau C.L., Eubanks S., et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 125 3 (2003) 533-542
9. Villard J. Immunity after organ transplantation. Swiss Med Wkly 136 5-6 (2006) 71-77
10. Hardy J.D., Webb W.R., Dalton M.L., et al. Lung homotransplantations in man. JAMA 186 (1963) 1065-1074
11. Veith F.J. Lung transplantation in perspective. N Engl J Med 314 18 (1986) 1186-1187
12. Derom F., Barbier F., Ringoir S., et al. Ten-month survival after lung homotransplantation in man. J Thorac Cardiovasc Surg 61 6 (1971) 835-846
13. Garrity Jr. E.R., and Mehra M.R. An update on clinical outcomes in heart and lung transplantation. Transplantation 77 9 Suppl (2004) S68-S74
14. Trulock E.P., Edwards L.B., Taylor D.O., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report-2005. J Heart Lung Transplant 24 8 (2005) 956-967
15. Shapiro R., Young J.B., Milford E.L., et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 5 (2005) 874-886
16. Meier-Kriesche H.U., Li S., Gruessner R.W., et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 6 (2006) 1111-1131
17. Orens J.B., Shearon T.H., Freudenburger R.S., et al. Thoracic organ transplantation in the United States, 1995-2004. Am J Transplant 6 (2006) 1188-1197
18. Borel J.F. Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity. Immunology 31 4 (1976) 631-641
19. Midtvedt K. Therapeutic drug monitoring of cyclosporine. Transplant Proc 36 Suppl 2 (2004) 430S-433S
20. Schreiber S.L., and Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunol Today 13 4 (1992) 136-142
21. Kahan B.D. Cyclosporine. [see comment]. N Engl J Med 321 25 (1989) 1725-1738
22. Lindholm A., and Kahan B.D. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 54 2 (1993) 205-218
23. Trulock E.P. Management of lung transplant rejection. Chest 103 5 (1993) 1566-1576
24. Kino T., Hatanaka H., Miyata S., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 40 9 (1987) 1256-1265
25. Briffa N., and Morris R.E. New immunosuppressive regimens in lung transplantation. Eur Respir J 10 11 (1997) 2630-2637
26. Sawada S., Suzuki G., Kawase Y., et al. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 139 6 (1987) 1797-1803
27. Peters D.H., Fitton A., Plosker G.L., et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 46 4 (1993) 746-794
28. Armitage J.M., Kormos R.L., Fung J., et al. The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 23 6 (1991) 3054-3057
29. McDiarmid S.V., Klintmalm G.B., and Busuttil R.W. FK506 conversion for intractable rejection of the liver allograft. Transpl Int 6 6 (1993) 305-312
30. Woodle E.S., Thistlethwaite J.R., Gordon J.H., et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation 62 5 (1996) 594-599
31. Horning N.R., Lynch J.P., Sundaresan S.R., et al. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant 17 8 (1998) 761-767
32. Mentzer Jr. R.M., Jahania M.S., and Lasley R.D. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The US Multicenter FK506 Study Group. Transplantation 65 1 (1998) 109-113
33. Onsager D.R., Canver C.C., Jahania M.S., et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant 18 5 (1999) 448-455
34. Sarahrudi K., Estenne M., Corris P., et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 127 4 (2004) 1126-1132
35. Griffith B.P., Bando K., Hardesty R.L., et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation 57 6 (1994) 848-851
36. Keenan R.J., Konishi H., Kawai A., et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. [see comment]. Ann Thorac Surg 60 3 (1995) 580-584 [discussion: 584-5]
37. Treede H., Klepetko W., Reichenspurner H., et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 20 5 (2001) 511-517
38. Kur F., Reichenspurner H., Meiser B.M., et al. Tacrolimus (FK506) as primary immunosuppressant after lung transplantation. Thorac Cardiovasc Surg 47 3 (1999) 174-178
39. Martel R.R., Klicius J., and Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 55 1 (1977) 48-51
40. Calne R.Y., Collier D.S., Lim S., et al. Rapamycin for immunosuppression in organ allografting. [see comment]. Lancet 2 8656 (1989) 227
41. Hausen B., Boeke K., Berry G.J., et al. Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 18 2 (1999) 150-159
42. Azzola A., Havryk A., Chhajed P., et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 77 2 (2004) 275-280
43. Alho H.S., Salminen U.S., Maasilta P.K., et al. Epithelial apoptosis in experimental obliterative airway disease after lung transplantation. J Heart Lung Transplant 22 9 (2003) 1014-1022
44. Salminen U.S., Maasilta P.K., Taskinen E.I., et al. Prevention of small airway obliteration in a swine heterotopic lung allograft model. J Heart Lung Transplant 19 2 (2000) 193-206
45. Ussetti P., Laporta R., de Pablo A., et al. Rapamycin in lung transplantation: preliminary results. Transplant Proc 35 5 (2003) 1974-1977
46. Hernandez R.L., Gil P.U., Gallo C.G., et al. Rapamycin in lung transplantation. Transplant Proc 37 9 (2005) 3999-4000
47. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. [see comment]. N Engl J Med 349 9 (2003) 847-858
48. Valentine V.G., Love R.B., Snell G.I., et al. Everolimus (RAD) shows superiority over azathioprine to inhibit the decline of pulmonary function in stable lung transplant recipients: 24-month results of a multicenter, randomized double-blind study. [abstract 403]. Am J Transplant 4 Suppl 8 (2004) 269
49. Knoop C., Haverich A., and Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J 23 1 (2004) 159-171
50. O'Hair D.P., Cantu E., McGregor C., et al. Preliminary experience with mycophenolate mofetil used after lung transplantation. J Heart Lung Transplant 17 9 (1998) 864-868
51. Ross D.J., Waters P.F., Levine M., et al. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant 17 8 (1998) 768-774
52. Zuckermann A., Klepetko W., Birsan T., et al. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. J Heart Lung Transplant 18 5 (1999) 432-440
53. Palmer S.M., Baz M.A., Sanders L., et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 71 12 (2001) 1772-1776
54. McNeil K., Glanville A.R., Wahlers T., et al. Comparison of mycophenolate aofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant tecipients. Transplantation 81 7 (2006) 998-1003
55. Garrity Jr. E.R., Villanueva J., Bhorade S.M., et al. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 71 6 (2001) 773-777
56. Brock M.V., Borja M.C., Ferber L., et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 20 12 (2001) 1282-1290
57. McCurry K.R., Iacono A., Zeevi A., et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 130 2 (2005) 528-537
58. Hausen B., Gummert J., Berry G.J., et al. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Transplantation 69 4 (2000) 488-496
59. Gerbase M.W., de Perrot M., Spiliopoulos A., et al. Selective monoclonal versus polyclonal antibodies for induction of immunosuppression in lung recipients. Clin Pharmacol Ther 72 1 (2002) 103
60. Borro J.M., De la Torre M., Miguelez C., et al. Comparative study of basiliximab treatment in lung transplantation. Transplant Proc 37 9 (2005) 3996-3998
61. Shitrit D., Bendayan D., Sulkes J., et al. Successful steroid withdrawal in lung transplant recipients: result of a pilot study. Respir Med 99 5 (2005) 596-601
62. Napoli K.L. The FTY720 story. Ther Drug Monit 22 1 (2000) 47-51
63. Konishi K., Inobe M., Yamada A., et al. Combination treatment with FTY720 and CTLA4IgG preserves the respiratory epithelium and prevents obliterative disease in a murine airway model. J Heart Lung Transplant 21 6 (2002) 692-700
64. Kita Y., Nogimura H., Ida M., et al. Combined therapy of CTLA4Ig-gene transfection with FTY720 administration in rat lung allografts. Transplant Proc 34 5 (2002) 1437-1440
65. O'Hagan A.R., Stillwell P.C., Arroliga A., et al. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest 115 5 (1999) 1459-1462
66. Villanueva J., Bhorade S.M., Robinson J.A., et al. Extracorporeal photopheresis for the treatment of lung allograft rejection. Ann Transplant 5 3 (2000) 44-47
67. Lamioni A., Parisi F., Isacchi G., et al. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 79 7 (2005) 846-850
68. Valentine V.G., Robbins R.C., Wehner J.H., et al. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. [see comment]. Chest 109 5 (1996) 1184-1189
69. Diamond D.A., Michalski J.M., Lynch J.P., et al. Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation. Int J Radiat Oncol Biol Phys 41 4 (1998) 795-800
70. Fisher A.J., Rutherford R.M., Bozzino J., et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 5 3 (2005) 537-543
71. Sayegh M.H., and Turka L.A. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 338 25 (1998) 1813-1821
72. Azuma H., Chandraker A., Nadeau K., et al. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. [see comment]. Proc Natl Acad Sci USA 93 22 (1996) 12439-12444
73. Pham S.M., Mitruka S.N., Youm W., et al. Mixed hematopoietic chimerism induces donor-specific tolerance for lung allografts in rodents. Am J Respir Crit Care Med 159 1 (1999) 199-205
74. Pierog J., Gazdhar A., Stammberger U., et al. Synergistic effect of low dose cyclosporine A and human interleukin 10 overexpression on acute rejection in rat lung allotransplantation. Eur J Cardiothorac Surg 27 6 (2005) 1030-1035